Mark A. Socinski, MD
Dr. Mark A. Socinski is the Executive Medical Director for the Florida Hospital Cancer Institute. He was previously the Professor of Medicine and Thoracic Surgery and Director of the Lung Cancer Section, Division of Hematology/Oncology at the University of Pittsburgh in Pittsburgh, Pennsylvania. He was Co-Director of the UPMC Lung Cancer Center of Excellence and the Lung and Thoracic Malignancies Program and the Clinical Associate Director of the Specialized Program of Research Excellence (SPORE) in Lung Cancer at the University of Pittsburgh Medical Center.
Dr. Socinski is board-certified in internal medicine and medical oncology and is a member of several professional organizations including the American College of Physicians, the American Society of Clinical Oncology, Cancer and Leukemia Group B, the International Association for the Study of Lung Cancer, and the American College of Chest Physicians. He has written many manuscripts, principally in the field of thoracic oncology.
Dr. Socinski earned an MD degree from the University of Vermont in Burlington. He completed an internal medicine internship and residency at Harvard Medical School/Beth Israel Hospital in Boston. He then completed medical oncology and clinical medicine fellowships at the Dana-Farber Cancer Institute, Harvard Medical School.
Jamie E. Chaft, MD
Dr. Jamie E. Chaft is an Assistant Attending Physician in the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center. She trained in medical oncology at Memorial Sloan Kettering where she has since taken a faculty position treating and researching non–small cell lung cancer.
Dr. Chaft’s primary research focus is combined modality therapy for potentially curable lung cancers, including surgery, radiation therapy, and systemic therapy. She writes, leads, and participates in clinical trials evaluating systemic therapies that are typically used in advanced lung cancer in patients with early stage lung cancers. Dr. Chaft is a member of the American Society of Clinical Oncology, the International Association of the Study of Lung Cancer, and the Eastern Cooperative Oncology Group. She is also a member of the American Association for Thoracic Surgery Working Group for stage IIIA disease and has many publications on the topic of non–small cell lung cancer.
She earned an MD degree from the New York University School of Medicine and completed her internal medicine training at New York Presbyterian – Weill Cornell.
Sarah B. Goldberg, MD, MPH
Dr. Sarah Goldberg is an Assistant Professor of Medicine in the section of Medical Oncology at the Yale School of Medicine and Yale Cancer Center. At Yale, she takes care of patients in the thoracic oncology group and conducts clinical and translational research on lung cancer.
The focus of her research is investigating biomarkers and novel treatment strategies in non–small cell lung cancer. Specifically, her work includes studying targeted therapy and immunotherapy, with a particular interest in patients with brain metastases.
Dr. Goldberg earned an MD degree from the Mount Sinai School of Medicine and a Masters of Public Health from Harvard University. She completed an internal medicine residency at Massachusetts General Hospital followed by a medical oncology fellowship at the Dana-Farber Cancer Institute and Massachusetts General Hospital.
Roy S. Herbst, MD, PhD
Dr. Roy S. Herbst is Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, Director of the Thoracic Oncology Research Program, and Associate Director for Translational Research at Yale Cancer Center (YCC) and Yale School of Medicine, New Haven, Connecticut.
Dr. Herbst has led phase 1 development of several new-generation targeted agents for non–small cell lung cancer (NSCLC), including gefitinib, erlotinib, cetuximab, and bevacizumab. Dr. Herbst was co-leader of BATTLE-1 and co-leads the BATTLE-2 clinical trial program. He served as co-leader of the Developmental Therapeutics Program for the YCC support grant. Herbst’s laboratory work focuses on angiogenesis and epidermal growth factor receptor/vascular endothelial growth factor receptor inhibition in NSCLC and targeting KRAS-activated pathways. This work has been translated from preclinical to clinical settings in multiple phase 2 and 3 studies.
Dr. Herbst has authored or co-authored more than 300 publications, including peer-reviewed journal articles, abstracts, and book chapters. His work has appeared in many prominent journals, such as the Journal of Clinical Oncology, Clinical Cancer Research, Lancet, and The New England Journal of Medicine. His work published in Nature was awarded the 2015 Herbert Pardes Clinical Research Excellence Award by the Clinical Research Forum.
Dr. Herbst was a member of the National Cancer Policy Forum, for which he organized an Institute of Medicine meeting focused on policy issues in personalized medicine. He is a member of the American Association of Cancer Research, where he chairs the Tobacco Task Force, as well as the American Society of Clinical Oncology. Dr. Herbst is a fellow of the American College of Physicians and an elected member of the Association of American Physicians. He is Vice Chair for developmental therapeutics for Southwestern Oncology Group’s (SWOG) Lung Committee, Principal Investigator of the SWOG 0819 trial, and Steering Committee Chair for the Lung Master Protocol. In 2015, his team at Yale was awarded a lung cancer SPORE by the National Cancer Institute.
Dr. Herbst earned a PhD degree in molecular cell biology from The Rockefeller University, an MD degree from Cornell University Medical College, and an MS degree in clinical translational research from Harvard University. He completed an internship and residency at Harvard Medical School, along with a clinical fellowship in medicine. He also completed a medical oncology fellowship at Dana Farber Cancer Institute and a medical hematology fellowship at Brigham and Women’s Hospital.
Mark G. Kris, MD
Dr. Mark G. Kris is an Attending Physician in the Thoracic Oncology Service at Memorial Hospital, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York. He is the first incumbent of the William and Joy Ruane Chair in Thoracic Oncology. He is a Professor of Medicine at the Weill Cornell Medical College. Since 2012, he has served as the Lead Physician for the Memorial Sloan Kettering – IBM Watson Collaboration.
Dr. Kris is author or co-author of over 300 original scientific publications. He holds memberships in the American Association for Cancer Research, the American Society of Clinical Oncology, and the International Association for the Study of Lung Cancer. Dr. Kris served as a member of the guideline panels on non–small cell lung cancers and antiemetics for the National Comprehensive Cancer Center Network from 1995 to 2015. He served as co-chair of the American Society of Clinical Oncology guideline panel for adjuvant chemotherapy and radiation for non–small cell lung cancers. Dr. Kris serves on the Antiemetic Guideline Panel for the American Society of Clinical Oncology. He is a Fellow of the American College of Physicians, The American College of Chest Physicians, and The American Society of Clinical Oncology. Dr. Kris received the first American Society of Clinical Oncology Humanitarian Award in 2011. He also received the Annie Blount Storrs Award from Calvary Hospital in 2014.
Dr. Kris is a specialist in lung cancers and other tumors arising in the chest. He is particularly interested in developing strategies to choose treatments for patients based on molecular characteristics of their tumor specimens. Dr. Kris’ research also includes the evaluation of new anticancer agents (particularly those targeting lung cancers), multimodality therapy (using surgery, radiation and drugs together to improve outcomes for individuals with thoracic cancers), and the training of the IBM Watson cognitive computer to assist physicians in choosing the best treatments for their patients with cancers.
Dr. Kris graduated from Fordham University. After earning an MD degree from Weill Cornell Medical College, he served as chief medical resident and fellow in medical oncology at Memorial Sloan Kettering Cancer Center.
Corey J. Langer, MD, FACP
Dr. Corey J. Langer is a Professor of Medicine in the Hematology/Oncology Division at the University of Pennsylvania in Philadelphia, Pennsylvania, where he serves as Director of Thoracic Oncology in the Abramson Cancer Center and leads I-TOP (the interdisciplinary thoracic oncology program).
Dr. Langer is a fellow of the American College of Physicians and is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the International Society for Geriatric Oncology, and the International Association for the Study of Lung Cancer (IASLC). He served as chair of the medical oncology subcommittee of the Radiation Therapy Oncology Group (RTOG), as well as the Group Vice-Chair before its transition to NRG, and he continues to maintain a leadership role within the newly formed group, co-chairing its medical oncology subcommittee. He also serves on the core thoracic and head and neck committees of both the Eastern Cooperative Oncology Group and RTOG.
Dr. Langer has contributed numerous articles (>190) and abstracts to the medical literature. His work on head and neck squamous cell cancer, non–small cell lung cancer, small cell carcinoma of the lung, and malignant mesothelioma has appeared in The New England Journal of Medicine, Journal of the National Cancer Institute, and Seminars in Oncology, among others. His work has also been presented at the national meetings of ASCO, AACR, ASH, and the IASLC. He is currently on the editorial boards of Clinical Lung Cancer and Clinical Advances in Hematology and Oncology. He is the chair of the Perspectives in Thoracic Oncology meeting, which convenes annually in New York City.
Dr. Langer earned an MD degree from Boston University and completed his internship and residency in medicine at the Graduate Hospital of the University of Pennsylvania in Philadelphia. Additional postgraduate training included a fellowship in hematology/oncology at the Penn Presbyterian Medical Center and a fellowship in oncology at American Oncologic Hospital/FCCC.
Benjamin Levy, MD
Dr. Benjamin Levy is currently the Medical Director of Thoracic Medical Oncology for Mount Sinai Health Systems and the Associate Medical Director of the Cancer Clinical Trials Office (CCTO) for Mount Sinai Hospital. His main focus is the comprehensive clinical care and research development for patients with thoracic malignancies, with particular emphasis on non–small cell lung cancer. In this effort, he has developed a robust clinical research portfolio that evaluates novel therapies including immunotherapy for lung cancer and is actively searching for genetic alterations that may predict sensitivity to such drugs.
In addition to his clinical and research duties, Dr. Levy serves as Associate Editor for the ASCO University Committee, where he helps develop educational web-based content for oncologists across the country. He currently serves on the editorial board for the Journal of Clinical Oncology and serves as an ad hoc reviewer for other journals including Clinical Lung Cancer and The Oncologist. Dr Levy actively publishes in peer-reviewed journals including the Journal of the National Comprehensive Cancer Network, Journal of Oncology Practice, and the Journal of Thoracic Oncology.
Dr. Levy earned an MD degree from the Medical College of Georgia in Augusta; completed his internal medicine residency at Georgetown Univeristy Hospital in Washington, DC; and his fellowship in hematology/oncology at New York Presbyterian – Weill Cornell in New York City.
Roman Perez-Soler, MD
Dr. Roman Perez-Soler is Chairman of the Department of Oncology at Montefiore Medical Center, Chief of the Division of Medical Oncology in the Department of Medicine at Albert Einstein College of Medicine, and Deputy Director of the Albert Einstein Cancer Center.
His clinical and translational research is focused on novel approaches for the treatment for lung cancer and has been funded by the National Institutes of Health. He has made important contributions in the areas of epidermal growth factor receptor inhibitors, topoisomerase I inhibitors, and novel delivery systems including aerosolization for the treatment of bronchial premalignancy.
Dr. Perez-Soler is currently RO1 funded for the development of inhaled demethylating therapies for lung cancer and is principal investigator of the National Cancer Insitute–funded K12 Paul Calabresi Award for Clinical Oncology at Albert Einstein Cancer Center, a program that has trained 13 young clinical investigators. Dr. Perez-Soler holds 17 patents and has published more 200 papers and book chapters.
Dr. Perez-Soler earned an MD degree from the Universidad Autonoma in Barcelona, Spain, and completed a residency at the Universidad de Barcelona and a fellowship in medical oncology at the MD Anderson Cancer Center.
Rathi Pillai, MD
Dr. Rathi Pillai is an Assistant Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine.
Dr. Pillai’s primary research interest is the identification of biomarkers that may predict response to immune checkpoint therapies, such as antibodies against Programmed Death Protein 1 (PD-1) and its ligand in lung cancer. She is involved in phase 1 studies of checkpoint inhibitors in lung cancer.
Dr. Pillai earned an MD at the University of Texas Southwestern Medical Center in Dallas. She completed a residency in internal medicine and a fellowship in hematology and medical oncology at Emory University, where she was Chief ellow in her final year.
Suresh S. Ramalingam, MD
Dr. Suresh Ramalingam is Professor of Hematology and Medical Oncology and Director of the Division of Medical Oncology at the Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia.
Dr. Ramalingam serves as the Chair of the ECOG-ACRIN thoracic malignancies committee. He also serves on the Editorial Board of leading cancer journals such as the Journal of Clinical Oncology, Annals of Oncology, Cancer, Clinical Lung Cancer, and Translational Lung Cancer Research. Dr. Ramalingam is the recipient of several awards, including the James R. Eckman Award for Excellence in Teaching from the Department of Hematology and Medical Oncology, Emory University; and the Distinguished Cancer Scholar Award, Georgia Cancer Coalition.
Dr. Ramalingam’s research interests include the development of novel anti-cancer agents and evaluation of methods to individualize therapies for patients. He has conducted several clinical trials with molecularly targeted agents in the treatment of small cell and non–small cell lung cancer. He has published more than 200 original manuscripts, review articles, editorials, and book chapters.
Dr. Ramalingam earned an MD degree at Kilpauk Medical College, Madras, India. He completed his residency in internal medicine at Wayne State University, Detroit, Michigan, where he also served as chief medical resident. He completed a fellowship in hematology and medical oncology at the University of Pittsburgh Medical Center in Pennsylvania.
Gregory J. Riely, MD, PhD
Dr. Gregory J. Riely is a Medical Oncologist in the Department of Medicine at Memorial Sloan Kettering Cancer Center.
His primary research focuses on the treatment of patients with thymic tumors as well as non–small cell lung cancer with specific mutations (EGFR, KRAS, BRAF, or EML4-ALK mutant non–small cell lung cancer). He has authored and co-authored numerous peer-reviewed articles.
Dr. Riely earned PhD and MD degrees from Case Western Reserve University in Cleveland, Ohio. He completed a residency at New York-Presbyterian Hospital/Weill Cornell Medical Center and fellowship training in medical oncology at Memorial Sloan Kettering Cancer Center.
Heather Wakelee, MD
Dr. Heather Wakelee is an Associate Professor of Medicine at Stanford University in the Division of Oncology, where she leads the thoracic medical oncology research program. She is the faculty director of the Stanford University Cancer Clinical Trials Office.
Dr. Wakelee’s focus is on clinical research in thoracic malignancies including lung cancer and thymic malignancies. Dr. Wakelee has led multiple investigator-initiated protocols and played a central role in clinical trials with bevacizumab and many other antiangiogenic agents. She is the principal investigator on the multinational E1505 study of adjuvant bevacizumab in non–small cell lung cancer. She has also run clinical trials of drugs and drug combinations focused on overcoming epidermal growth factor receptor and anaplastic lymphoma kinase inhibitor resistance, Met inhibitors, and novel immune modulatory agents. Additional areas of interest include lung cancer in never-smokers and novel lung cancer biomarkers. She is author or co-author of more than 100 articles about thoracic malignancies.
Dr. Wakelee is an active member of the Eastern Cooperative Oncology Group, the International Association for the Study of Lung Cancer, the American Society of Clinical Oncology and the International Thymic Malignancies Interest Group.
Dr. Wakelee earned an MD degree from Johns Hopkins University School of Medicine in Baltimore, Maryland. She completed an internship, residency, and fellowship at Stanford University School of Medicine.